DiaMedica Therapeutics

DiaMedica Therapeutics

DMAC· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +46.6% in FY2025

Rick Pauls is the CEO of DiaMedica Therapeutics and was paid $2.7M in FY2025 (Dec), up 76%.

Pay$100 in the stock at the end of FY21 → $213
CEO pay is from each DiaMedica Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Rick PaulsFY2025
  2. 2Julie Krop, M.D.FY2025
  3. 3Scott KellenFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

DiaMedica Therapeutics paid its 3 named executives $5.7M in total in FY2025 (Dec). CEO Rick Pauls was paid $2.7M of that.

Name
Rick PaulsPresident and Chief Executive Officer
Julie Krop, M.D.Chief Medical OfficerNot disclosedNot disclosed
Scott KellenChief Financial Officer and Secretary

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2025 (Dec) proxy of DiaMedica Therapeutics names 18 peer companies for pay. Among DiaMedica Therapeutics and these peers, CEO pay was 2nd highest of 5 and total shareholder return was 2nd highest of 5.

2nd highest of 5in DiaMedica Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$1.2M$3.3M

2nd highest of 5in DiaMedica Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$95$15,536

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • James ParsonsChair · 10 yr on the boardIndependentAudit (Chair)—Paid as an executive
  • Richard Kuntz, M.D.Director · 2 yr on the boardIndependentCompensation, Scientific and Clinical Research (Chair)—Paid as an executive
  • Tanya LewisDirector · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance, Scientific and Clinical Research—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    DiaMedica Therapeutics CFO pay rose 51% to $1.2M. The stock rose 47% in FY2025 (Dec).
    DEF 14A
  2. Pay
    DiaMedica Therapeutics CEO pay rose 76% to $2.7M. The stock rose 47% in FY2025 (Dec).
    DEF 14A
  3. Pay
    DiaMedica Therapeutics CFO pay rose 29% to $814.0K. The stock rose 91% in FY2024 (Dec).
    DEF 14A
  4. Pay
    DiaMedica Therapeutics CEO pay rose 28% to $1.6M. The stock rose 91% in FY2024 (Dec).
    DEF 14A
  5. Pay
    DiaMedica Therapeutics CFO pay rose 12% to $632.2K. The stock rose 80% in FY2023 (Dec).
    DEF 14A
  6. Pay
    DiaMedica Therapeutics CEO pay rose 12% to $1.2M. The stock rose 80% in FY2023 (Dec).
    DEF 14A
  7. Pay
    DiaMedica Therapeutics Former Chief Medical Officer pay fell 41% to $596.1K. The stock rose 80% in FY2023 (Dec).
    DEF 14A
  8. Board
    Tanya Lewis joined the board of DiaMedica Therapeutics. Tanya Lewis sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 1, 2026FY2025
Annual report10-KMar 30, 2026FY2025
Proxy statementDEF 14AMar 28, 2025FY2024
Annual report10-KMar 17, 2025FY2024
Proxy statementDEF 14AApr 4, 2024FY2023
Annual report10-KMar 19, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data